Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.


Main focus: Genomic medicines for ocular diseases

Company stage: Pre-clinical

Diseases (gene editing): Undisclosed

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: Paris, France



Partners: Intellia Therapeutics

SparingVision is a gene therapy focused company, that develops medicines for the treatment of ocular diseases. The company is currently developing multiple pre-clinical programmes, however, the company's engagement in gene editing comes through recent collaboration with Intellia Therapeutics. As part of the collaboration, SparingVision has been granted a licence to develop medicines for up to three ocular targets. Furthermore, the companies will together develop AAV vectors and LNP-based approaches to address delivery of CRISPR-Cas9 genome-editing reagents to the retina.



The CMN Collection of Delivery Articles
Company: SparingVision
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine